Vedolizumab for Crohn's disease

被引：13
作者：
Mosli, Mahmoud H. [1 ,2 ]
Feagan, Brian G. [1 ]
机构：
[1] Univ Western Ontario, Robarts Res Inst, Dept Med, London, ON N6A 5K8, Canada
[2] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Dept Med, Jeddah 21413, Saudi Arabia
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2013年 / 13卷 / 03期
关键词：
Crohn's disease; MAdCAM-1; monoclonal antibody; therapy; vedolizumab; alpha; 4; beta; 7; integrin; INFLAMMATORY-BOWEL-DISEASE; INTERCELLULAR-ADHESION MOLECULE-1; PLACEBO-CONTROLLED TRIAL; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; ANTISENSE OLIGODEOXYNUCLEOTIDE; HUMANIZED ANTIBODY; CERTOLIZUMAB PEGOL; CLINICAL-RESPONSE; DOUBLE-BLIND;
D O I：
10.1517/14712598.2013.770835
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Introduction: Crohn's disease (CD) is a chronic inflammatory disorder of unknown aetiology. Currently, approved therapies that include prednisone, anti-metabolites and TNF antagonists, are often ineffective and frequently cause adverse effects. As a result, patients with CD can develop serious complications that adversely affect quality of life. Consequently, new treatment options are needed. Areas covered: This review discusses the potential role of vedolizumab, a humanised monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of CD. All randomised placebo-controlled trials that evaluated vedolizumab for the treatment of CD were reviewed and safety and efficacy data evaluated. Expert opinion: Vedolizumab is an effective and well-tolerated drug that is an important advance for the treatment of CD.
引用
收藏
页码：455 / 463
页数：9
相关论文
共 64 条
  • [1] MECHANISMS OF DISEASE Inflammatory Bowel Disease
    Abraham, Clara
    Cho, Judy H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) : 2066 - 2078
  • [2] Progressive Multifocal Leukoencephalopathy and Newer Biological Agents
    Berger, Joseph R.
    [J]. DRUG SAFETY, 2010, 33 (11) : 969 - 983
  • [3] CEPEK KL, 1993, J IMMUNOL, V150, P3459
  • [4] ChemoCentryx, 2012, CCR9 PROGR
  • [5] ClinicaTrials.gov, 2012, OP LAB STUD VED MLN0
  • [6] ClinicaTrials.gov, 2012, SAF TOL PHARM PHARM
  • [7] ClinicaTrials.gov, 2012, STUD VED MLN0002 PAT
  • [8] Evolving medical therapies for ulcerative colitis.
    Cohen R.D.
    [J]. Current Gastroenterology Reports, 2002, 4 (6) : 497 - 505
  • [9] Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
    Colombel, Jean Frederic
    Sandborn, William J.
    Reinisch, Walter
    Mantzaris, Gerassimos J.
    Kornbluth, Asher
    Rachmilewitz, Daniel
    Lichtiger, Simon
    D'Haens, Geert
    Diamond, Robert H.
    Broussard, Delma L.
    Tang, Kezhen L.
    van der Woude, C. Janneke
    Rutgeerts, Paul
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) : 1383 - 1395
  • [10] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
    Colombel, Jean-Frederic
    Sandborn, William J.
    Rutgeerts, Paul
    Enns, Robert
    Hanauer, Stephen B.
    Panaccione, Remo
    Schreiber, Stefan
    Byczkowski, Dan
    Li, Ju
    Kent, Jeffrey D.
    Pollack, Paul F.
    [J]. GASTROENTEROLOGY, 2007, 132 (01) : 52 - 65
1234567